708 reports of this reaction
2.0% of all LITHIUM CARBONATE reports
#8 most reported adverse reaction
DEPRESSION is the #8 most commonly reported adverse reaction for LITHIUM CARBONATE, manufactured by ANI Pharmaceuticals, Inc.. There are 708 FDA adverse event reports linking LITHIUM CARBONATE to DEPRESSION. This represents approximately 2.0% of all 35,528 adverse event reports for this drug.
Patients taking LITHIUM CARBONATE who experience depression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEPRESSION is a less commonly reported adverse event for LITHIUM CARBONATE, but still significant enough to appear in the safety profile.
In addition to depression, the following adverse reactions have been reported for LITHIUM CARBONATE:
The following drugs have also been linked to depression in FDA adverse event reports:
DEPRESSION has been reported as an adverse event in 708 FDA reports for LITHIUM CARBONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEPRESSION accounts for approximately 2.0% of all adverse event reports for LITHIUM CARBONATE, making it a notable side effect.
If you experience depression while taking LITHIUM CARBONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.